ReviewExpert opinion on drug discovery2016
Drug target identification in protozoan parasites.
Review in Expert opinion on drug discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Drug Repurposing in Parasitology: New Uses for Old Drugs to Be Used Through the Host-Parasite Interface.Pathogens (Basel, Switzerland) · 2026Review
- Navigating imaging artifacts: challenges with visualizing intrinsically fluorescent antimalarials.Frontiers in parasitology · 2026Article
- Challenges and Achievements in the In Vitro Culture ofPathogens (Basel, Switzerland) · 2025Article
- Uncovering the Mechanism of Action of Antiprotozoal Agents: A Survey on Photoaffinity Labeling Strategy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mitochondrial Reactive Oxygen Species in Infection and Immunity.Biomolecules · 2024Review
- Current perspectives and difficulties in the design of acaricides and repellents from plant-derived compounds for tick control.Experimental & applied acarology · 2024Review
- Discovery of potent inhibitors targeting Glutathione S-transferase of Wuchereria bancrofti: a step toward the development of effective anti-filariasis drugs.Molecular diversity · 2024Article
- Comparative efficacy of buparvaquone and imidocarb in inhibiting theFrontiers in pharmacology · 2024Article
- Proteomics Applications inPathogens (Basel, Switzerland) · 2023Review
- Analysis ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Residue Depletion of Imidocarb in Bovine Tissues by UPLC-MS/MS.Animals : an open access journal from MDPI · 2022Article
- Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1.Journal of medicinal chemistry · 2022Article
- In silico Methods for Identification of Potential Therapeutic Targets.Interdisciplinary sciences, computational life sciences · 2022Review
- The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.Frontiers in cellular and infection microbiology · 2022Article
- Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads.Expert review of anti-infective therapy · 2021Article
- How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins.Molecular pharmacology · 2021Article
- Melittin as a promising anti-protozoan peptide: current knowledge and future prospects.AMB Express · 2021Review
- An Overview of the Synthesis and Antimicrobial, Antiprotozoal, and Antitumor Activity of Thiazole and Bisthiazole Derivatives.Molecules (Basel, Switzerland) · 2021Review
- Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice.International journal of antimicrobial agents · 2020Article
- Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionDespite the fact that diseases caused by protozoan parasites represent serious challenges for public health, animal production and welfare, only a limited panel of drugs has been marketed for clinical applications. AREAS COVERED: Herein, the authors investigate two strategies, namely whole organism screening and target-based drug design. The present pharmacopoeia has resulted from whole organism screening, and the mode of action and targets of selected drugs are discussed. However, the more recent extensive genome sequencing efforts and the development of dry and wet lab genomics and proteomics that allow high-throughput screening of interactions between micromolecules and recombinant proteins has resulted in target-based drug design as the predominant focus in anti-parasitic drug development. Selected examples of target-based drug design studies are presented, and calcium-dependent protein kinases, important drug targets in apicomplexan parasites, are discussed in more detail. EXPERT OPINION: Despite the enormous efforts in target-based drug development, this approach has not yet generated market-ready antiprotozoal drugs. However, whole-organism screening approaches, comprising of both in vitro and in vivo investigations, should not be disregarded. The repurposing of already approved and marketed drugs could be a suitable strategy to avoid fastidious approval procedures, especially in the case of neglected or veterinary parasitoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.